Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
about
Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortalityClostridium difficile-induced colitis in mice is independent of leukotrienesMechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabCirculating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosisNovel approaches to treating Clostridium difficile-associated colitis.Overview of Clostridium difficile infection: implications for ChinaAntibodies for treatment of Clostridium difficile infection.Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.Novel therapeutic strategies for Clostridium difficile infections.Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.Pathogenic effects of glucosyltransferase from Clostridium difficile toxins.Bezlotoxumab: First Global Approval.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.Fidaxomicin and OP-1118 inhibit C. difficile toxin A- and B-mediated inflammatory responses via inhibition of NF-κB activity.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
P2860
Q30413111-BFCEFDF6-3338-41AC-8F78-4510B9EAA490Q34644107-2B7269ED-F472-4933-B76A-D82783E018B6Q34955629-9DBD1A6A-A7D2-4F5E-8D10-BB248979EF5FQ34994695-119F5739-E838-43E8-8C99-79CEEAB0878AQ35862915-60D3966E-BD77-4096-B90E-02E7D36248B9Q37609133-438D1184-F5F3-493A-80B7-B431F7E668D2Q38208794-84D83023-CD5D-466C-B41C-FD85D9B26A35Q38597041-8F3D3D76-D34B-4BDB-89C4-1809A4FD62C2Q38632664-15315793-0B8C-42E7-9DE3-F850E2982BB1Q38737485-9E2B7173-64A4-43EE-84E1-193A569A76FDQ38797967-69BA27C2-E148-43D0-8ABB-B9BE112DE8B3Q39025270-9B49A360-8643-46CA-AA14-C58FC9018E02Q40095035-6FAA753A-0132-43D1-BB08-0C1BC69E423FQ40125340-5AE694F5-D33C-4A93-94FB-69D51BE29186Q41834229-753EB48A-150D-439A-A945-58183106AD34Q46412261-0C9493D9-9DE0-453F-B23E-190A9663772CQ48059378-8711CEAF-4184-4A39-B507-7D6A02C671CEQ49201152-67933343-E687-42B5-822B-6DF0D395EF00Q49841486-C5835820-8540-40F1-9B91-7F17D2FF76B2
P2860
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Human monoclonal antibodies ag ...... nd peripheral blood monocytes.
@en
type
label
Human monoclonal antibodies ag ...... nd peripheral blood monocytes.
@en
prefLabel
Human monoclonal antibodies ag ...... nd peripheral blood monocytes.
@en
P2093
P2860
P356
P1476
Human monoclonal antibodies ag ...... nd peripheral blood monocytes.
@en
P2093
Charalabos Pothoulakis
Ciarán P Kelly
David Q Shih
Hon Wai Koon
Jun Hwan Yoo
Samantha Ho
Stephan R Targan
Tressia C Hing
Xinhua Chen
P2860
P304
P356
10.1128/AAC.02633-12
P407
P577
2013-04-29T00:00:00Z